Nuo Therapeutics Inc (AURX) - Financial and Strategic SWOT Analysis Review

GlobalData
36 Pages - GLDATA63561
$125.00

Nuo Therapeutics Inc (AURX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Nuo Therapeutics Inc (Nuo Therapeutics), formerly Cytomedix, is a biomedical company that specializes in biodynamic therapies in the area of wound care. It focuses on commercializing cell-based technologies, which bind the regenerative capacity of the human body to trigger natural healing. The company's flagship product, Aurix System, is a biodynamic hematogel designed to harness a patient's innate regenerative abilities to manage a wide range of wounds. Aurix is US FDA approved platelet and plasma therapy system for managing a wide range of ulcers and exuding wounds, including leg ulcer, diabetic ulcer, pressure ulcer, and all severities such as full thickness, partial thickness and complex wounds. The company has its facilities in Nashville, Tennessee; and Durham, North Carolina. Nuo Therapeutics is headquartered in Gaithersburg, Maryland, the US.

Nuo Therapeutics Inc Key Recent Developments

Jul 05,2017: Nuo Therapeutics Receives Advisory Opinion Waiver for Medicare Part B Co-Payments for Patients in Aurix CED Clinical Studies
Apr 10,2017: Nuo Therapeutics appoints Dr. Paul D. Mintz to its board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

'

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Nuo Therapeutics Inc - Key Facts 5
Nuo Therapeutics Inc - Key Employees 6
Nuo Therapeutics Inc - Key Employee Biographies 7
Nuo Therapeutics Inc - Major Products and Services 8
Nuo Therapeutics Inc - History 9
Nuo Therapeutics Inc - Company Statement 11
Nuo Therapeutics Inc - Locations And Subsidiaries 12
Head Office 12
Other Locations & Subsidiaries 12
Section 2 – Company Analysis 13
Company Overview 13
Nuo Therapeutics Inc - Business Description 14
Nuo Therapeutics Inc - Corporate Strategy 15
Nuo Therapeutics Inc - SWOT Analysis 16
SWOT Analysis - Overview 16
Nuo Therapeutics Inc - Strengths 16
Nuo Therapeutics Inc - Weaknesses 17
Nuo Therapeutics Inc - Opportunities 18
Nuo Therapeutics Inc - Threats 19
Nuo Therapeutics Inc - Key Competitors 20
Section 3 – Company Financial Ratios 21
Financial Ratios - Capital Market Ratios 21
Financial Ratios - Annual Ratios 22
Performance Chart 25
Financial Performance 25
Financial Ratios - Interim Ratios 26
Financial Ratios - Ratio Charts 27
Section 4 – Company’s Lifesciences Financial Deals and Alliances 28
Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Nuo Therapeutics Inc, Recent Deals Summary 30
Section 5 – Company’s Recent Developments 31
Jul 05, 2017: Nuo Therapeutics Receives Advisory Opinion Waiver for Medicare Part B Co-Payments for Patients in Aurix CED Clinical Studies 31
Section 6 – Appendix 32
Methodology 32
Ratio Definitions 32
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Nuo Therapeutics Inc, Key Facts 5
Nuo Therapeutics Inc, Key Employees 6
Nuo Therapeutics Inc, Key Employee Biographies 7
Nuo Therapeutics Inc, Major Products and Services 8
Nuo Therapeutics Inc, History 9
Nuo Therapeutics Inc, Other Locations 12
Nuo Therapeutics Inc, Subsidiaries 12
Nuo Therapeutics Inc, Key Competitors 20
Nuo Therapeutics Inc, Ratios based on current share price 21
Nuo Therapeutics Inc, Annual Ratios 22
Nuo Therapeutics Inc, Annual Ratios (Cont...1) 23
Nuo Therapeutics Inc, Annual Ratios (Cont...2) 24
Nuo Therapeutics Inc, Interim Ratios 26
Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 29
Nuo Therapeutics Inc, Recent Deals Summary 30
Currency Codes 32
Capital Market Ratios 32
Equity Ratios 33
Profitability Ratios 33
Cost Ratios 34
Liquidity Ratios 34
Leverage Ratios 35
Efficiency Ratios 35

List of Figures
Nuo Therapeutics Inc, Performance Chart (2013 - 2017) 25
Nuo Therapeutics Inc, Ratio Charts 27
Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 28
Nuo Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 29

$125.00

Research Assistance

We can help you find
data and analyses
relevant to your needs,
or prepare a custom report.

Please contact us at [email protected]
or +1 212 564 2838

 

Custom Research

Contact us to speak
with your industry analyst.

[email protected] 
+1 212 564 2838

 



Discount Codes

Request Discount Codes
for reports of interest to you.

[email protected]
+1 212 564 2838